Dare Bioscience Inc
Change company Symbol lookup
Select an option...
DARE Dare Bioscience Inc
KALU Kaiser Aluminum Corp
SEED Origin Agritech Ltd
DFFN Diffusion Pharmaceuticals Inc
PCSB PCSB Financial Corp
BHB Bar Harbor Bankshares
EH Ehang Holdings Ltd
CNSL Consolidated Communications Holdings Inc
WLFC Willis Lease Finance Corp
HCI Hci Group Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Value
Company profile

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Closing Price
$0.90
Day's Change
0.0236 (2.69%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.9199
Day's Low
0.84
Volume
(Light)
Volume:
82,158

10-day average volume:
141,735
82,158

Display:

Providers:

UpdateCancel
7 providers
April 01, 2020
Dare Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene(R)

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it received a Notice of Award of $730,722 in a grant supporting the Ovaprene(R) postcoital test (PCT) clinical study research from the Eunice Kennedy...(Globe Newswire)

March 30, 2020
Dare Bioscience Reports 2019 Financial Results and Provides a Company Update

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the year ended December 31, 2019 and provided a company update. "During the fourth quarter of 2019 and into early 2020, we made...(Globe Newswire)

March 24, 2020
Dare Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on March 30, 2020, to review its financial results for the fourth quarter...(Globe Newswire)

March 10, 2020
Dare Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis

DARE-BV1 demonstrated an 86% clinical cure rate in evaluable subjects at the test-of-cure visit after a single administration in an investigator-initiated proof of concept study, which is higher than the clinical cure rates of current FDA-approved...(Globe Newswire)

March 09, 2020
Dare Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced the presentation of positive findings from a previously reported investigational study that used thermography technology to assess the pharmacodynamics of...(Globe Newswire)

February 27, 2020
Dare Bioscience to Present at the Cowen 40th Annual Health Care Conference

Dare Bioscience, Inc.(NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the Cowen 40 Annual Health Care Conference on Wednesday, March 4...(Globe Newswire)

February 12, 2020
Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company's Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its...(Globe Newswire)

February 06, 2020
Dare Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, announced that it has been notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum stockholders' equity requirement set forth in...(Globe Newswire)

February 05, 2020
Dare Bioscience to Present at the 2020 BIO CEO & Investor Conference

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Tuesday, February 11...(Globe Newswire)

January 30, 2020
Dare Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum bid price rule in Nasdaq Listing Rule...(Globe Newswire)

January 15, 2020
Dare Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene(R) Licensing Agreement and General Corporate Update

Dare Bioscience, Inc.(NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, January 22, 2020, to discuss the recently announced licensing...(Globe Newswire)

January 13, 2020
Bayer and Dare Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene (R), an Investigational Hormone-Free, Monthly Contraceptive

Bayer, a leader in women's health, and Dare Bioscience, Inc. (NASDAQ:DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health, announced today that the companies have signed a license...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.